24 July, 2014 17:52 IST
News
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS (19-NOV-12)
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*


Live News
Rupee remains stable against dollar to settle at 60.10 - 24-Jul-2014 17:31
Diamond Offshore Q2 profit plunges as sales, margin fall - 24-Jul-2014 17:30
CoreLogic Q2 earnings plummet, miss forecasts - 24-Jul-2014 17:09
India needs strong law for benefit of mankind: PK Malhotra - 24-Jul-2014 17:00
Umpqua Holdings Q2 profit plunges, but beats estimate - 24-Jul-2014 16:57
Experts welcome hike in FDI for insurance industry - 24-Jul-2014 16:55
Tractor Supply Company Q2 earnings climb, miss estimates - 24-Jul-2014 16:48
India's mobile services market to reach USD 19.2 bn in 2014: Gartner - 24-Jul-2014 16:45
FDI cap of 49% in insurance industry is a welcome move: Rajesh Sud - 24-Jul-2014 16:40
AT&T Q2 profit falls but still beats estimates - 24-Jul-2014 16:28
FICCI welcomes CBDT's action plan to dispose of 90% high value pending appeals - 24-Jul-2014 16:25
more...
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type   sfsbm4 into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer